E.V. KHAZOVA, O.V. BULASHOVA, M.I. MALKOVA, V.N. OSLOPOV

Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation 420012

Khazova E.V. — Cand. Med. Sc., Assistant Lecturer of the Department of Propedeutics of Internal Diseases, tel. +7-905-313-97-10, e-mail: hazova_elena@mail.ru

Bulashova O.V. — D. Med. Sc., Professor of the Department of Propedeutics of Internal Diseases, tel. (843) 296-14-03, e-mail: boulashova@yandex.ru

Malkova M.I. — Cand. Med. Sc., Assistant Lecturer of the Department of Propedeutics of Internal Diseases, tel. +7-960-051-61-16, e-mail: marimalk@yandex.ru

Oslopov V.N. — D. Med. Sc., Professor, Head of the Department of Propedeutics of Internal Diseases, tel. +7-905-316-25-35, e-mail: kpvbol@yandex.ru

Variability in the distribution of genes in populations logically involves obtaining additional markers in conjunction with phenotypic markers of the course and outcomes of chronic heart failure (CHF). The purpose of the study is a comprehensive assessment of clinical and genetic factors that influence the course and outcomes of heart failure in conjunction with the ion-transporting function of the cell membrane. 150 patients of hospital register with CHF, aged 64,6±10,4 years, were examined. Polymorphisms in genes AGT (M235T), ACE (I/D), and ADRB2 (Arg16Gly, Gln27Glu) were determined by PCR, and speed Na⁺-Li⁺-countertransport (CT) in the erythrocyte membrane — by Canessa M. method (1980). The differences in the distribution of the surveyed patients by the speed of Na⁺-Li⁺-CT were revealed. The ranking of patients by the speed of Na⁺-Li⁺-CT revealed significant predictors of heart failure outcomes for each quartile of speed of Na⁺-Li⁺-CT.

Key words: chronic heart failure, prognosis, AGT ( M235T ), ACE (I / D) and ADRB2 (Arg16Gly, Gln27Glu) gene polymorphisms, Na⁺-Li⁺-countertransport.

 

 

REFERENCES

1. Ambrosy A., Pang P., Khan S. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur. Heart J., 2013, vol. 34 (11), pp. 835-843.

2. Paulus W.J., Carsten T., Sanderson J.E. et al.How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J., 2007, vol. 28, pp. 2539-2550.

3. Kaldara-Papatheodorou E.E., Terrovitis J.V., Nanas J.N. Anemia in heart failure: should we supplement iron in patients with chronic heart failure? Pol arch med wewn, 2010, vol. 120 (9), pp. 354-360.

4. Singh R., Murphy J.J., Brennan G. et al. Long term outcome in heart failure: do patients with reduced and preserved ejection fraction differ? European Heart Journal, 2012, vol. 33, pp. 517-518.

5. McMurray J.J., Ezekowitz J.A., Lewis B.S. et al.Left Ventricular Systolic Dysfunction, Heart Failure and the Risk of Stroke and Systemic Embolism in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. Circ Heart Fail., 2013, vol. 6 (3), pp. 451-460.

6. Liu M., Lee A.P., Sun J.P. et al. Risk stratification for 1 year mortality in patients with heart failure and normal ejection fraction. European Heart Journal, 2012, suppl. 33, pp. 518-519.

7. Sergeeva L.I., Panev N.I. General patterns and pathogenetic significance of postinfarction remodeling in the progression of chronic heart failure. Byulleten’ SO RAMN, 2008, no. 5 (133), pp. 121-126 (in Russ.).

8. Konradi A.O. Treatment of hypertension in specific groups of patients. Left ventricular hypertrophy. Arterial’naya gipertenziya, 2005, no. 11, pp. 34-37 (in Russ.).

9. Kobalava Zh.D., Kotovskaya Yu.V., Safarova A.F. et al. Disproportionately high left ventricular myocardial mass in hypertensive patients: clinical association and remodeling. Kardiologiya, 2008, no. 11, pp. 19-29 (in Russ.).

10. Malikov V.E., Evsikov E.M., Kutuzova T.G. et al. Pharmacological correction of symptoms and remodeling in refractory forms of chronic heart failure with left ventricular dysfunction. Rossiyskiy kardiologicheskiy zhurnal, 2008, no. 5, pp. 56-62 (in Russ.).

11. Mareev V.Yu., Ageev F.T., Arutyunov G.P. et al. National recommendations PRAs, RKO and RNMOT for diagnosis and treatment of CHF (fourth revision). Serdechnaya nedostatochnost’, 2013, vol. 14, no. 7 (81). 472 s. (in Russ.)

12. Krasnova O.A., Sitnikova M.Yu., Ivanov S.G. The relationship of polymorphic variants of genes ACE (I / D), AGT (M235T) and beta2-adrenoceptor (Q27E and G16R) with the clinical phenotype of patients systolic CHF. Serdechnaya nedostatochnost’, 2012, no. 13 (4), pp. 200-204 (in Russ.).

13. Teplyakov A.T., Shilov S.N., Berezikova E.N. et al. Pharmacogenetic polymorphisms control I / D ACE gene — the dominant risk factor for chronic heart failure and the target for the treatment of enalapril. Kardiologiya, 2013, no. 3, pp. 9-14 (in Russ.).

14. Khazova E.V., Bulashova O.V., Oslopov V.N. et al. Genetic aspects of myocardial remodeling in patients with decompensated chronic heart failure. Prakticheskaya meditsina. “Novye tekhnologii v meditsine. Kardiologiya”, 2012, no. 5 (60), pp. 114-117 (in Russ.).

15. Membrane theory of hypertension Y. Postnova practice population and clinical studies of hypertension from the perspective of this theory. Reduced osmotic resistance of erythrocytes — a new characterization of membrane disorders. Materialy III Rossiyskoy nauchno-prakticheskoy konferentsii “Zdorov’e cheloveka v XXI veke”. Kazan, 2011. Pp. 82-95 (in Russ.).

16. Bulashova O.V., Oslopov V.N., Matveeva T.V. Klinicheskoe znachenie opredeleniya skorosti Na+/Li+-protivotransporta u bol’nykh s khronicheskoy serdechnoy nedostatochnost’yu. Kazanskiy meditsinskiy zhurnal, 2003, vol. 84, no. 6, pp. 409-413 (in Russ.).

17. Slepukha E.G. Klinicheskoe i prognosticheskoe znachenie opredeleniya iontrasportnykh funktsiy kletochnykh membran pri khronicheskoy serdechnoy nedostatochnosti: avtoref. dis. … kand. med. nauk [Clinical and prognostic value of the determination iontrasportnyh functions of cell membranes in chronic heart failure]. Kazan, 2010. 23 p.

18. Khazova E.V., Bulashova O.V., Oslopov V.N. Variability angiotensinogen gene in patients with chronic heart failure at different speeds Na + / Li +-countertransport. Prakticheskaya meditsina. “Kardiologiya”, 2013, no. 3 (71), pp. 63-67.

19. Mareev V.Yu., Danielyan M.O., Belenkov Yu.N. Comparative characteristics of patients with CHF, depending on the size of the PV on the results of the Russian multicenter study AGE-O-CHF. Serdechnaya nedostatochnost’, 2006, no. 7 (4), pp. 164-171.

20. Ettinger O.A., Uskova O.V., Gendlin G.E. et al. Anemia in patients with chronic heart failure: the role of iron deficiency and its correction. Consilium medicum, 2011, vol. 13, no. 5, pp. 121-127 (in Russ.).